Survival, quality of life and impact of right heart failure in patients with acute cardiogenic shock treated with ECMO

Heart & Lung ◽  
2016 ◽  
Vol 45 (5) ◽  
pp. 409-415 ◽  
Author(s):  
Felix Schoenrath ◽  
Dennis Hoch ◽  
Francesco Maisano ◽  
Christoph T. Starck ◽  
Burkhardt Seifert ◽  
...  
Author(s):  
Karen Aide Santillan Reyes ◽  
Viridiana Peláez Hernández ◽  
Laura Arely Martínez Bautista ◽  
Karla Leticia Rosales Castillo ◽  
Lizzbett Luna Rodríguez ◽  
...  

2020 ◽  
Vol 76 (17) ◽  
pp. B73
Author(s):  
Navin Kapur ◽  
Katherine Thayer ◽  
Arthur Garan ◽  
Jaime Hernandez Montfort ◽  
Claudius Mahr ◽  
...  

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
H Thyagaturu ◽  
K Shah ◽  
S Li ◽  
A Kumar

Abstract Introduction Influenza infection could cause systemic inflammatory response and lead to increase sympathetic tone. The association and impact of atrial fibrillation (AF) on Influenza has not been well studied. Purpose To evaluate the association of atrial fibrillation with mortality and resource utilization in influenza hospitalizations. Methods We queried 2018 National Inpatient Sample (NIS) database to identify influenza and AF hospitalizations using appropriate ICD-10 codes. Influenza with AF group was compared to influenza without AF. Chi-square test and linear regression were used for categorical and continuous variables, respectively. Multivariate logistic regression was used to adjust for potential hospital and patient confounders (age, sex, race, diabetes, systolic heart failure, chronic kidney disease, obesity, charlson co-morbidity index, hospital location, teaching status, bed size and income status). Discharge weights provided in the database was used to calculate the national estimates. STATA 16.1 was used to perform all statistical analysis. Results 345,419 weighted influenza hospitalizations were identified. Of which, 78,824 (22.8%) of them had atrial fibrillation. Influenza patients with AF were older (mean age: 77 vs. 65 yrs; p<0.01) but had similar number of female (52% vs 48%; p<0.01) compared to influenza patients without AF. After adjusting for potential hospital and patient level confounders, we observed statistically significant increase in mortality [Adjusted Odds Ratio (aOR): 1.5 (1.4–1.7); p<0.01], length of stay [6.5 vs 5.4 days; p<0.01], total hospitalization charges [USD: $65,302 vs $54,149; p<0.01], right heart failure [aOR: 2.4 (1.6–3.6); p<0.01], cardiogenic shock [aOR: 1.9 (1.5–2.5); p<0.01] in influenza patients with AF when compared to those without AF. Conclusion Presence of AF is an independent predictor of mortality, length of stay, hospitalization charges, right heart failure and cardiogenic shock in hospitalized patients with influenza. This study helps to assume prognosis and raise awareness on the intensity of care needed toward these patients. FUNDunding Acknowledgement Type of funding sources: None.


Reumatismo ◽  
2021 ◽  
Vol 72 (4) ◽  
pp. 228-246
Author(s):  
D. Giuggioli ◽  
C. Bruni ◽  
F. Cacciapaglia ◽  
F. Dardi ◽  
A. De Cata ◽  
...  

The term pulmonary arterial hypertension (PAH) identifies a heterogeneous group of diseases characterized by a progressive increase in pulmonary arterial resistance (PVR), which causes a significant burden in terms of quality of life, right heart failure and premature death. The pathogenesis of PAH is not completely clear: the remodeling of the small pulmonary vessels is crucial, causing an increase in the resistance of the pulmonary circle. Its diagnosis is based on cardiac catheterization of the right heart. According to the present hemodynamic definition of pulmonary hypertension (PH) proposed by the Guidelines of the European Society of Cardiology/European Respiratory Society (ESC-ERS), the mean pulmonary arterial pressure (mPAP) values are ≥25 mmHg. In case of PAH, apart from an mPAP value ≥25 mmHg, patients must have a >3 Wood units increase in PVR and normal pressure values of the left heart. PH is a pathophysiological condition observed in more than 40 different diseases, while PAH is a primary disease of the pulmonary bloodstream potentially treatable with specific drugs. PAH is a severe complication of systemic sclerosis (SSc) affecting about 10% of the patients. Due to the devastating nature of SSc-PAH, there is a clear need to systematically adopt appropriate screening programs. In fact, despite awareness of the negative impact of SSc-PAH on quality of life and survival, as well as on the severity of lung function, at the moment standardized and shared guidelines and/or screening programs for the diagnosis and the subsequent early treatment of PAH in SSc are not available. The aim of the present paper is to highlight the lights and shadows of SSc-PAH, unraveling the unmet clinical needs on this topic with a proposal of clinical-diagnostic and therapeutic guidelines.


Sign in / Sign up

Export Citation Format

Share Document